Anixa Biosciences Reports First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial
News related to:Anixa Biosciences, Inc · 2 min read
SAN JOSE, Calif., Oct. 5, 2026 /CourierPR/ -- Anixa Biosciences has announced a significant breakthrough in its ongoing Phase 1 clinical trial for a novel CAR-T therapy targeting ovarian cancer. The company reported that a patient in the fifth dose cohort exhibited stable disease for three months after treatment, marking the first such response in the company’s CAR-T cell therapy trial. This development is particularly encouraging as it suggests the potential for long-term disease control in patients with recurrent ovarian cancer.
The patient, who received a dose of 1×10⁷ CAR-positive cells per kilogram of body weight following lymphodepletion, is the highest dose level evaluated to date in the study. To date, no dose-limiting toxicities have been observed in any of the patients enrolled in the trial. The trial, which is being conducted at Moffitt Cancer Center, is evaluating liraltagene autoleucel, or lira-cel, Anixa's novel CAR-T therapy targeting the follicle-stimulating hormone receptor (FSHR), which is selectively expressed on ovarian cancer cells.
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, expressed encouragement regarding the early findings.
The ongoing Phase 1 trial (ClinicalTrials.gov NCT05316129) is enrolling adult women with recurrent ovarian cancer who have progressed after at least two prior therapies. Anixa's CAR-T technology was developed by Jose R. Conejo-Garcia, M.D., Ph.D., Professor of Immunology in the Department of Integrative Immunobiology at the Duke University School of Medicine. The company's therapeutic portfolio includes liraltagene autoleucel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology.
Anixa Biosciences is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. The company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer.
The company's forward-looking statements, including those concerning its expectations, involve risks, uncertainties, and other factors, some of which are beyond its control, which may cause its actual results, performance, or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties, and factors include, but are not limited to, those factors set forth in the company's most recent Annual Report on Form 10-K as well as in its Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.